DDInter1570 DDInter899
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Ranolazine {u} (Compound) resembles {v} (Compound) Guaifenesin
Ranolazine {u} (Compound) resembles {v} (Compound) Bupivacaine
Ranolazine {u} (Compound) binds {v} (Gene) CYP2D6
Ranolazine {u} (Compound) upregulates {v} (Gene) DENND2D
Ranolazine {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ranolazine {u} (Compound) downregulates {v} (Gene) ATP6V1D
Ranolazine {u} (Compound) causes {v} (Side Effect) Underweight
Ranolazine (Compound) resembles Guaifenesin (Compound)
Ranolazine (Compound) resembles Bupivacaine (Compound)
Ranolazine (Compound) binds CYP2D6 (Gene)
Ranolazine (Compound) upregulates DENND2D (Gene)
Ranolazine (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ranolazine (Compound) downregulates ATP6V1D (Gene)
Ranolazine (Compound) causes Underweight (Side Effect)